Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apixaban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 known ✓ | P00742 | 20/20 | 1.00 |
| ▸ | F2 | P00734 | 5/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19086463 | 0.99 | F10 (0.98) | F10F2SLC29A1 | |
| Apixaban SCHEMBL15534161 | 0.99 | F10 (0.98) | F10F2SLC29A1 | |
| Apixaban SCHEMBL14672486 | 0.99 | F10 (0.98) | F10F2SLC29A1 | |
| Apixaban SCHEMBL5445904 | 0.99 | F10 (0.98) | F10F2SLC29A1 | |
| SCHEMBL16730331 | 0.97 | F10 (0.94) | F10F2SLC29A1 | |
| Apixaban SCHEMBL28348493 | 0.96 | F10 (0.93) | F10F2SLC29A1 | |
| Apixaban SCHEMBL19991448 | 0.96 | F10 (0.93) | F10F2SLC29A1 | |
| Apixaban SCHEMBL13321443 | 0.95 | F10 (0.91) | F10F2SLC29A1 | |
| Apixaban SCHEMBL22581184 | 0.95 | F10 (0.90) | F10F2SLC29A1 | |
| Apixaban SCHEMBL31267125 | 0.93 | F10 (0.88) | F10F2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11794 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137672-A1 | SUSTAINED-RELEASE TABLET COMPRISING APIXABAN | REXPHARMTECH CO., LTD (KR) | 2026-05-21 | — | — | US | claimed |
| WO-2026103722-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COAGULATION FACTOR XI (FXI) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2026-05-21 | — | — | WO | claimed |
| CN-121064189-B | Synthesis method of apixaban | 广东工业大学 | 2026-05-19 | — | — | CN | claimed |
| WO-2026098615-A1 | COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF IN PREPARATION OF DRUGS FOR TREATING CARDIOVASCULAR AND CEREBROVASCULAR DISEASES | 上海东西智荟生物医药有限公司 | 2026-05-15 | — | — | WO | claimed |
| EP-4313104-B1 | DC009 FOR TREATING ACUTE ISCHEMIC STROKE | LUMOSA THERAPEUTICS CO LTD (TW) | 2026-05-13 | — | — | EP | claimed |
| EP-4739305-A1 | BUDIODARONE FOR CARDIOVERSION | Xyra, LLC (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| EP-4412586-B1 | APIXABAN SUSPENSION AND PREPARATION METHOD | PHARMA DATA RES AND DEVELOPMENT SINGLE MEMBER S A (GR) | 2026-05-13 | — | — | EP | claimed |
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | ORPHELION AB (SE) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2007117621-A1 | USE OF COMBINATION PREPARATIONS CONTAINING THROMBIN RECEPTOR ANTAGONISTS FOR TREATING CARDIOVASCULAR DISORDERS | SCHERING CORPORATION (US) | 2007-10-18 | — | — | WO | claimed |
| US-20070238674-A1 | TRA COMBINATION THERAPIES | SCHERING CORPORATION | 2007-10-11 | — | — | US | claimed |
| US-20070203178-A1 | CRYSTALLINE SOLVATES OF APIXABAN | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-30 | — | — | US | claimed |
| US-20070191306-A1 | FACTOR Xa INHIBITOR FORMULATION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | US | claimed |
| EP-1807086-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-07-18 | — | — | EP | claimed |
| WO-2007022165-A2 | FACTOR XA INHIBITOR INCLUSION COMPLEX WITH CYCLODEXTRIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-22 | — | — | WO | claimed |
| WO-2006110726-A2 | DOSAGE FORMULATIONS AND METHODS OF TREATMENT AND PREVENTION | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | claimed |
| WO-2006078331-A2 | CRYSTALLIZATION VIA HIGH-SHEAR TRANSFORMATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-27 | — | — | WO | claimed |
| US-20060160841-A1 | Crystallization via high-shear transformation | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-20 | — | — | US | claimed |
| WO-2006045756-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-04 | — | — | WO | claimed |